Table 4.
Total Benefits and total cumulated benefits per year (in €2008 Billion)
| Blood-lead concentrations range (μg/L) | Bmed | Bsocietal | Total benefits | Hypothetical threshold values (μg/L) | Total cumulated benefits |
|---|---|---|---|---|---|
| 15 ≤ B-Pb < 24 | 0.198 | 11.8 | 11.99 (1) | B-Pb ≥ 15 | 22.72 (1+2+3) |
| 24 ≤ B-Pb < 100 | 0.083 | 10.2 | 10.28 (2) | B-Pb ≥ 24 | 10.72 (2+3) |
| B-Pb ≥ 100 | 0.016 | 0.44 | 0.44 (3) | B-Pb ≥ 100 | 0.44 |
Table 4 shows the estimated total benefits ranged from blood-lead concentrations and total cumulated benefits based on three hypothetical values per year. We first differenced the estimated medical benefits (Bmed) and the societal benefits (Bsocietal) ranged from blood-lead concentrations:
The 15-24 μg/L Bmed, the 24-100 μg/L Bmed and the ≥ 100 μg/L Bmed are the Bscreening15-24 (€0.198 Billion), the Bscreening24-100 (€0.083 billion) and the Btreatment≥ 100 (€0.016 billion), respectively.
The 15-24 μg/L Bsocietal, the 24-100 μg/L Bsocietal and the ≥ 100 μg/L Bsocietal are the Bearn15-24 discounted (€11.8 billions), The Bearn24-100 discounted (€ 10.2 billions) and the Bearn≥ 100 discounted added to the Bspec.ed≥ 100 , the Bcrime≥ 100 and the Bother≥ 100 (€0.44 billion), respectively. The Bspec.ed≥ 100 equal to €0.01453 billion [(10% of the French population of children 3-6 years) ((79.8%*38,958) + (20.1%*48,255))], the Bcrime≥ 100 equal to € 0.0618 billion and the Bother≥ 100 equal to €0.0427 billion, which are the intangible avoided costs. We estimated the total benefits (Bmed +Bsocietal) ranged from blood-lead concentrations: €11.99 billions (1), €10,28 billions (2) and € 0.44 billion (3).
We secondly estimated total cumulated benefits per year based on the three hypothetical threshold values, above 15, 24 and 100 μg/L. We obtained €22.72 billions (1+2+3), €10.72 billions (2+3) and € 0.44 billion (3), respectively.